|1.||Kaya, Murat: 4 articles (03/2008 - 11/2005)|
|2.||Akman, Hülya: 4 articles (03/2008 - 11/2005)|
|3.||Somuncu, Salih: 4 articles (03/2008 - 11/2005)|
|4.||Cakmak, Murat: 4 articles (03/2008 - 11/2005)|
|5.||Polat, Ayse: 3 articles (04/2008 - 05/2003)|
|6.||Camdeviren, Handan: 3 articles (10/2006 - 04/2005)|
|7.||Caglayan, Osman: 3 articles (05/2006 - 11/2005)|
|8.||Bagdatoglu, Ozlen: 3 articles (04/2005 - 05/2003)|
|9.||Bagdatoglu, Celal: 3 articles (04/2005 - 07/2002)|
|10.||Kanik, Arzu: 3 articles (06/2003 - 07/2002)|
12/01/2005 - "Protective effects of trapidil in lung after abdominal aorta induced ischemia-reperfusion injury: an experimental study."
12/01/2005 - "We aimed to investigate the protective effects of trapidil after the occlusion of abdominal aorta and the reperfusion injury in lung. "
03/01/2008 - "Ischemia-reperfusion injury of rabbit ovary and protective effect of trapidil: an experimental study."
02/01/2009 - "We evaluated the effect of trapidil on the long-term histologic damage in testicular ischemia-reperfusion injury. "
02/01/2009 - "Protective effect of trapidil on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury."
|2.||Myocardial Ischemia (Ischemic Heart Diseases)
01/01/1982 - "These data suggest that trapidil may be an effective treatment for left ventricular failure due to myocardial ischemia by virtue of its potent positive inotropic effects associated with substantial increases in myocardial blood supply sufficient to counteract the increase in oxygen consumption."
11/10/1994 - "Within the framework of a user observations study, 4,014 patients with ischemic heart disease were treated with Trapidil and kept under observation for 12 weeks. "
01/01/2012 - "We investigated the effects of the antianginal drug trapidil, which has been shown to inhibit phosphodiesterase, on AV conduction disturbances in a canine model of acute myocardial ischemia. "
01/01/2012 - "Effects of the antianginal drug trapidil on atrioventricular conduction disturbances during acute myocardial ischemia."
11/10/1994 - "[Therapy of ischemic heart disease with Trapidil. "
04/01/2006 - "Overall results of this study show that both drugs are equally effective and safe for the short-term treatment of patients with chronic stable angina pectoris and that trapidil can be considered as therapeutically equivalent to ISDN."
05/01/1997 - "Oral trapidil therapy is safe and effective in stable angina pectoris and is equivalent to standard therapy with ISDN."
05/01/1997 - "We studied 95 patients with stable angina pectoris who were randomized into a double-blind parallel group study with either oral trapidil or ISDN. "
04/01/2006 - "Trapidil is as effective as isosorbide-dinitrate for treating stable angina pectoris: a multinational, multicenter, double-blind, randomized study."
05/01/1997 - "This study was undertaken to compare the antianginal efficacy of trapidil with that of isosorbide dinitrate (ISDN) in patients with stable angina pectoris. "
|4.||Pathologic Constriction (Stenosis)
11/01/1983 - "The observation of the head angiogram showed that trapidil improved the stenosis in the lingual and temporal arteries which was caused by HCD."
06/01/1992 - "Thus trapidil was useful in preventing intimal proliferation after PTCA, especially in patients with more than 30% residual stenosis after PTCA."
01/01/1999 - "The estimated rate of overall stenoses (intention-to-treat analysis) at 1 year showed a significant reduction in patients receiving trapidil and ticlopidine (group 2) as compared with heparin (33 vs. 57%; P =.047). "
06/01/1992 - "Furthermore, in the patients with residual stenosis of more than 30%, progression of stenosis was less in the trapidil group than in the aspirin-dipyridamole group. "
03/01/2008 - "The study has shown that trapidil treatment prevents ischemia induced oxidative damage in the ovarian tissues of rabbits."
03/01/2014 - "Trapidil caused a significant (P < 0.05) increase in SOD activity, as decreased MDA levels and significantly (P < 0.05) reduced the expression of Bax as compared with the ischemia-reperfusion (IR) control group. "
03/01/2008 - "We aimed to detect the protective effect of trapidil in ischemia-reperfusion (IR) injury due to ovarian torsion and detorsion. "
06/01/2003 - "Trapidil was used in a rat model of intestinal barrier dysfunction caused by intestinal ischemia for 40 minutes followed by reperfusion for 12 hours. "
06/01/2003 - "Effects of trapidil on intestinal mucosal barrier function and bacterial translocation after intestinal ischemia and reperfusion in an experimental rat model."
|1.||Isosorbide Dinitrate (Isordil)
|3.||Platelet-Derived Growth Factor
|4.||Aspirin (Acetylsalicylic Acid)
|7.||Proliferating Cell Nuclear Antigen (PCNA)
|8.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|4.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)
|5.||Blood Component Removal (Apheresis)